Free tool
FAERS Monitor: Iopidine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019779 or its brand name (Iopidine, Apraclonidine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1
Serious
1
100% of reports
Hospitalization
1
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- retinal haemorrhage1
- retinopathy1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,158 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| retinopathy | 1 | 5640.0 | 5462.0 | 1,409 |
| retinal haemorrhage | 1 | 2953.3 | 2885.6 | 737 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.